Jeffrey Allerton, MD
Hematology & Oncology · Cooperstown, NYNPI 1205886181
Payments from drug & device makers
Across 117 payments — averaging $611.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$66K
- Novocure Inc.$3K
- Novartis$288
- Astellas Pharma US Inc$287
- E.r. Squibb & Sons, L.L.C.$261
- Seagen Inc.$221
- plus $2K from 30 others
What the payments were for
- Consulting fees$66,00096%
- Food & beverage$2,1963%
- Education$7731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 10 | $66,000 |
| Novocure Inc. | 2 | $2,522 |
| Novartis | 8 | $288 |
| Astellas Pharma US Inc | 4 | $287 |
| E.r. Squibb & Sons, L.L.C. | 5 | $261 |
| Seagen Inc. | 4 | $221 |
| Pfizer | 11 | $207 |
| Regeneron Healthcare Solutions, Inc. | 7 | $171 |
| Bristol Myers Squibb | 9 | $165 |
| Merck | 9 | $163 |
| Sanofi | 3 | $143 |
| AVEO Pharmaceuticals, Inc. | 2 | $122 |
| Incyte Corporation | 2 | $116 |
| Daiichi Sankyo Inc. | 4 | $93 |
| AstraZeneca | 5 | $89 |
| Epizyme, Inc. | 1 | $83 |
| Lilly USA, LLC | 6 | $83 |
| Eisai Inc. | 4 | $75 |
| EMD Serono, Inc. | 2 | $57 |
| Iovance Biotherapeutics, Inc. | 2 | $48 |
| Johnson & Johnson | 2 | $44 |
| Pharmaessentia USA Corporation | 1 | $28 |
| Adaptive Biotechnologies Corporation | 1 | $28 |
| Amgen | 1 | $26 |
| Boehringer Ingelheim | 1 | $25 |
| Bayer | 1 | $25 |
| Exelixis Inc. | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Beigene USA, Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Gilead | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Morphosys, US Inc. | 1 | $14 |
| Array Biopharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$71,558 in reported general payments places this provider in the 70th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 23 | $91,453 |
| ValacyclovirValacyclovir Hcl | 19 | $725 |
| Anastrozole | 13 | $217 |
| Letrozole | 16 | $185 |
| Prochlorperazine Maleate | 12 | $156 |
| Prednisone | 16 | $121 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cooperstown
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Richard ZunigaBabylon$10.9M
- Scott TagawaNew York$10.3M
- Mohammad Abdul HayNew York$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.